The decision comes as Schumer is now the Senate’s #2 recipient of pharmaceutical industry campaign cash.
By David Sirota, The Lever
Senate Majority Leader Chuck Schumer (D-N.Y.) let a U.S. Senate adviser kill key parts of Democrats’ promised drug pricing legislation, as Schumer has become the Senate’s second largest recipient of pharmaceutical industry cash.

On Saturday, the Senate’s parliamentary adviser Elizabeth MacDonough — who Schumer can remove — issued a non-binding advisory opinion saying Democrats should remove provisions in their spending bill that would punish drugmakers for inflating their prices for patients in private health insurance plans. The provision could have saved $40 billion, according to one estimate.
“The exclusion of the private insurance price limits means there is little left that will reduce costs for the vast majority of Americans who receive health insurance through their private sector employer,” reported Politico.
MacDonough also advised Democrats against including a provision in their legislation to cap out-of-pocket insulin costs at $35 a month for people on private insurance plans. Democrats ultimately held a failed vote to overrule her on the insulin cap.
Recent Posts
Voters in Key States See AI Campaign Cash as More Politically Toxic Than AIPAC: Poll
October 8, 2026
Take Action Now “Candidates should seek support from the AI industry at their own peril.”By Jake Johnson, Common Dreams Polling data released…
Everything You’ve Been Told About Lethal Injection Is a Lie
October 8, 2026
Take Action Now Death by drugs is brutal—and designed for political optics. Christa Pike’s failed execution pulled back the curtain.By Arianna…
British Support For Israel Is Shattering
October 7, 2026
Take Action Now There is not a single member of the Foreign and Commonwealth Office who believes that Israel, under any leadership, would allow a…
I’ve Covered Death Row Cases for Nearly a Decade. What Happened to Christa Pike Wasn’t an Anomaly.
October 6, 2026
Take Action Now Several states have faced questions about the competence of their execution teams as major medical organizations have opposed…




